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Abstract
Control of transgene expression from long-term expression vectors can be achieved with inducible and regu-
lated promoters. The two most commonly used inducible systems employ doxycycline or mifepristone as the
drug activating a silent trans-activator, which is expressed from a constitutive promoter. We evaluated the al-
terations provoked by constitutive expression in the liver of rtTA2S-M2 (rtTA2; second-generation reverse tetra-
cycline-controlled trans-activator) and GLp65, which are the trans-activators of the doxycyline- and mifepris-
tone-inducible systems, respectively. To this end we performed transcriptomic analysis of mice expressing these
trans-activators in the liver over 1 month. rtTA2 expression induced alterations in a few genes (69 gene probe-
sets; false discovery rate [FDR], 0.05), whereas GLp65 caused more numerous changes (1059 gene probe-sets,
an FDR of 0.05). However, only 20 and 53 of the genes from the rtTA2 and GLp65 groups, respectively, showed
changes (R-fold  3). Functional assignments indicate that alterations were mild and of little general signifi-
cance. Few additional transcriptomic changes were observed when expressing trans-activators in the presence
of inducer drugs; most were due to the drugs themselves. These results and the absence of toxicity observed
in treated animals indicate that the two inducible systems are well tolerated and have little impact on the liver
transcriptome profile. The milder alterations found with the use of rtTA2 suggest that this system is possibly
safer for gene therapy applications.
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Introduction
GENE THERAPY has emerged as a potential alternative strat-egy for treating a wide variety of diseases. For many
applications long-term expression vectors are desirable.
These types of vectors, however, would require the use of
inducible and regulable promoters to adapt transgene ex-
pression to specific therapeutic needs. Moreover, these types
of promoter are essential when the transgene is a molecule
with strong biological activity and potential toxicity, as is the
case with immunostimulatory cytokines such as interleukin
(IL)-12 and interferon (IFN)- (Melero et al., 2001; Prieto et
al., 2004). Among the existing inducible systems, the Tet-reg-
ulatory system (Tet-on) and the progesterone receptor regu-
latory system (RU486-on) have been used most frequently
(Harvey and Caskey, 1998). Both methods have been suc-
cessfully employed in preclinical gene therapy applications
to treat liver cancer by expressing IL-12 in liver for a pro-
longed period of time (Wang et al., 2004; Zabala et al., 2004).
Inducible systems are based on the use of two expression
cassettes: one encoding a trans-activator (TA) protein and a
second containing the therapeutic gene driven by an in-
ducible promoter that can be activated by the TA. The TA is
a chimeric protein that comprises a ligand-binding domain
(LBD), a DNA-binding domain (DBD), and a transcriptional
activation domain (AD). The TA is expressed constitutively
as an inactive form that becomes active on binding of the in-
ducer to the LBD. This enables the TA to bind the inducible
promoter through the DBD, thus promoting transcription of
the therapeutic transgene by the AD.
The optimal version of the Tet-on system is based on the
use of protein rtTA2S-M2 (rtTA2; second-generation reverse
tetracycline-controlled trans-activator) as TA. rtTA2 contains
a tetracycline resistance (TetR) gene carrying five specific mu-
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tations, in which codon usage was optimized for mammalian
cells, and from which all potential splice donor and accep-
tor sites, as well as predicted mRNA hairpin structures, were
eliminated (Urlinger et al., 2000). The AD in rtTA2 is formed
by three copies of a minimal VP16 12-amino acid domain re-
placing the original larger VP16 130-amino acid AD present
in rtTA (Baron et al., 1997). All these modifications decreased
the toxicity and immunogenicity of the TA and reduced the
binding of the TA to the inducible promoter in the absence
of the inducer drug (Baron et al., 1997). Furthermore, rtTA2
can be fully induced with a 10-fold lower concentration of
doxycycline (Dox) as compared with rtTA, limiting poten-
tial drug-derived toxicity (Urlinger et al., 2000).
The optimized RU486-on system uses the progesterone an-
tagonist mifepristone (RU-486) as inducer and a chimeric
protein named GLp65 as TA (Wang et al., 1994). GLp65 is a
fusion of the yeast GAL4 DBD, a human progesterone re-
ceptor LBD containing a 19-amino acid carboxy-terminal
deletion (PRLBD), and the 269-amino acid carboxy-termi-
nal acidic AD from human p65 (Burcin et al., 1999). This lat-
ter protein is a member of the Rel protein family, usually
found as part of NF-B transcription complexes (Siebenlist
et al., 1994).
An important safety requirement for inducible systems is
that the TAs, in their active or inactive forms, do not inter-
fere with endogenous gene expression, or with cellular func-
tions. The fact that these chimeric proteins are formed by
functional domains derived from potent transcriptional fac-
tors could entail the risk of unwanted side effects due to ac-
tivation of endogenous promoters. In the case of rtTA it is
known that the VP16 AD can interact with many essential
transcription factors such as human ADA2 coactivator (Can-
dau et al., 1996), TFIIB, TFIIH, TFII40, TBP, and SAGA his-
tone-acetylating complex (Blau et al., 1996; Hall and Struhl,
2002). The reduction of this AD in rtTA2 probably eliminates
many potential interactions with cellular transcription fac-
tors, but further studies are necessary to analyze its toxicity
in vivo. Regarding GLp65, it has been described that its AD
can interact with transcription regulation and signaling fac-
tors such as TFIIB and TBP (Schmitz et al., 2004), SMRT (Es-
pinosa et al., 2003), CBP (Parry and Mackman, 1997), calmod-
ulin (Antonsson et al., 2003), protein phosphatase-2A (Yang
et al., 2001), and PARP-1 and C/EBP (Xia et al., 1997). In ad-
dition, the human progesterone receptor LBD present in
GLp65 can bind heat shock proteins and transcriptional coac-
tivators (Leonhardt and Edwards, 2002). All these potential
interactions could contribute to the toxicity of TAs, especially
taking into account that they will be expressed constitutively
as long as the vector remains in the transduced tissue.
Although no signs of toxicity derived from TA expression
have been observed in studies performed in vivo with the op-
timized Tet-on or RU486-on inducible system (Wang et al.,
2004; Zabala et al., 2004), the effects that prolonged expres-
sion of their respective TAs could have in the transduced or-
gan have not been evaluated in detail. Because of the po-
tential therapeutic applications of both inducible systems we
performed genome-wide microarray analysis in mice that
had expressed the respective TAs in the liver for 1 month.
This study showed only moderate changes in the gene ex-
pression profile of liver cells in the presence of rtTA2. Tran-
scriptomic changes were more numerous in the case of
GLp65 but no morphological or biochemical changes were
observed in the liver with either of the two TAs. Because
transcription regulation responds to mechanisms that are
highly conserved among mammals we believe that our data
could anticipate similar effects in humans.
Materials and Methods
Animal manipulation
Five- to 6-week-old female BALB/c mice were purchased
from Harlan Laboratories (Barcelona, Spain). Animals were
maintained under standard conditions and all procedures
were approved by the institutional ethics committee of the
University of Navarra (Pamplona, Spain). The hydrody-
namics (HD)-based procedure (Zhang et al., 1999) was used
to inject mice with 75 g of plasmid DNA resuspended in 2
ml of saline (0.9% NaCl). Animals receiving the inducer
drugs were injected intraperitoneally with doxycycline (Dox;
Sigma-Aldrich, St. Louis, MO) at a dose of 50 g/g in 200
l of saline solution or with mifepristone (RU-486; Sigma-
Aldrich) at a dose of 250 g/kg in 60 l of sesame oil. In-
ducers were administered on a daily basis during the 3 days
before sacrifice. Blood samples were collected at the indi-
cated time points by retro-orbital bleeding under inhalatory
anesthesia (isoflurane [Forane]; Abbott Laboratories, Abbott
Park, IL). Serum was recovered by double centrifugation at
10,000 rpm for 5 min and stored at -20°C until protein mea-
surement.
Plasmid construction and purification
EA-rtTA2 and EA-GLp65 plasmids derive from a pGL3-
basic vector in which the trans-activator (TA) genes rtTA2S-
M2 and GLp65, respectively, have been cloned down-
stream of the EalbPa1AT liver-specific promoter (Kramer et
al., 2003) (Fig. 1A). EA-rtTA2 was generated as described pre-
viously (Zabala et al., 2004). EA-rtTA2 carries a mutated im-
proved version of rtTA (rtTA2S-M2) (Urlinger et al., 2000). In
addition, EA-rtTA2 contains a shortened version of the VP16
domain with lower cell toxicity. EA-GLp65 was generated
by inserting the GLp65 gene from pSwitch plasmid (Invit-
rogen, Carlsbad, CA) into the XbaI and HindIII sites in
EalbPa1AT-luc (Kramer et al., 2003). GLp65 is a chimeric 
protein that contains three functional domains: the region for
binding to GAL4 sites in the inducible promoter, a mutated
human progesterone receptor for binding to RU-486, and the
p65 TA from the NF-B transcription factor. PGFPwpre plas-
mid contains the green fluorescent protein (GFP)-encoding
gene linked to the woodchuck hepatitis posttranscriptional
regulatory element (WPRE) downstream of the cytome-
galovirus (CMV) promoter. The expression cassette CMV-
GFP-wpre was isolated from pRRLsin18ppt with HindIII and
EcoRI and cloned into pGL3basic digested with the same en-
zymes to generate the PGFPwpre plasmid. pCMV was pur-
chased from Clontech (Mountain View, CA). In all cases plas-
mid DNA was purified from bacteria culture with an
EndoFree plasmid maxi kit (Qiagen, Hilden, Germany) and
stored in Tris–EDTA (TE) buffer solution at 20°C.
RNA isolation and RT
Animals were killed and liver samples were collected,
rapidly frozen in liquid nitrogen, and kept at 80°C. For
RNA extraction, a portion of liver tissue was homogenized
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in 1 ml of TRIzol reagent (Invitrogen) with an Ultra-Turrax
driver T.25 (Janke & Kunkel/Ika-Labortechnik, Staufen, Ger-
many), processed according to the manufacturer’s protocol,
and stored at –80°C until analysis. Samples for microarray
analysis were also purified with an RNeasy mini kit (Qia-
gen). Genomic DNA was eliminated from the samples by
treatment with DNase I (Invitrogen). For reverse transcrip-
tase polymerase chain reactions (RT-PCRs) cDNA was syn-
thesized with 2 g of total RNA in 50-l reaction mixtures
containing 0.8 mM dNTP mix, 5.3 mM p(dN)6 random
primer (Roche, Basel Switzerland), 4 mM dithiothreitol (DTT;
Invitrogen), 48 units of RNase inhibitor (Invitrogen), 240
units of Moloney murine leukemia virus (M-MLV) reverse
transcriptase (Invitrogen), and 10 l of reaction buffer pro-
vided by the enzyme supplier. Reactions were incubated at
37°C for 1 hr and at 95°C for 1 min.
Quantitative polymerase chain reaction
cDNA was quantified with iQ SYBR green supermix in an
iQ5 real-time PCR detection system (Bio-Rad, Hercules, CA).
Primers were designed (Table 1) to discriminate between ge-
nomic and cDNA sequences, except those specific for plas-
mid amplicons. PCR amplification was performed under the
following conditions: one cycle of 3 min at 95°C; followed
by 40 cycles of 15 sec at 95°C, 30 sec at 60°C (annealing tem-
perature of 58°C when amplifying Vim), 30 sec at 72°C, and
10 sec at 81°C (detection temperature of 79°C for GLp65 and
Bche); followed by a single final extension cycle of 72°C for
4 min. Immediately after the PCR, a melting curve was gen-
erated by raising the incubation temperature from 55 to 95°C
to confirm amplification specificity. The final PCR product
was also analyzed by agarose electrophoresis. Samples were
analyzed in duplicate and mRNA expression data were nor-
malized by comparison with phosphoglycerate kinase-1
(Pgk1) as an internal control, after checking for the high sta-
bility of expression of this gene under all experimental con-
ditions (data not shown). The amount of each transcript was
expressed according to the formula 2Ct(Pgk1)Ct(gene), where
Ct is the point at which the fluorescence rises appreciably
above background fluorescence.
RNA isolation, cDNA synthesis, and 
microarray hybridization
RNA was purified from mouse liver with a commercial kit
(Rneasy; Qiagen). RNA concentration was measured at 260 nm
(Ultrospec 2000; Pharmacia Biotech, Uppsala, Sweden) and its
purity and quality were determined with an RNA 6000 Nano
Chip kit (Agilent Technologies, Palo Alto, CA). RNA was then
used to synthesize complementary RNA (cRNA) probes for
hybridization to Affymetrix GeneChip mouse genome 430A
2.0 high-density oligonucleotide microarrays (Affymetrix,
Santa Clara, CA), which include 22,690 oligonucleotide probe
sets corresponding to about 14,000 mouse genes, according to
protocols described in the Gene Expression Analysis Techni-
cal Manual (see http://www.affymetrix.com/support/techni-
cal/manual/expression_manual.affx [accessed October 2008]).
In brief, total RNA was reverse transcribed into double-
stranded complementary DNA (cDNA) with an oligo(dT)24
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TABLE 1. PRIMERS USED IN STUDY
Gene symbol GenBank accession no. Primer sequence Fragment length (bp)
mRNA
Mouse Mat1a NM_133653 Sense: 5-CTCTGGTGTCCTTCCCTGGC-3 200
Antisense: 5-GGTACTTGGCTGGCACCACA-3
Mouse Col1a2 NM_007743 Sense: 5-TGCTCAGCTTTGTGGATACG-3 370
Antisense: 5-CCAGCAGGTCCTTGGAAACC-3
Mouse Orm2 MN_011016 Sense: 5-CAATGAGACCCTGAGCTGG-3 230
Antisense: 5-CTTGGAGAGGGTCCCATTCT-3
Mouse Vim NM_011701 Sense: 5-ACCTGGCCGAGGACATCAT-3 238
Antisense: 5-ATCTGGACATGCTGTTCCTG-3
Mouse Saa3 NM_011315 Sense: 5-CAGGATGAAGCCTTCCATTG-3 249
Antisense: 5-AGCCTCTCTGGCATCACTGA-3
Mouse Nr3c1 NM_008173 Sense: 5-GGAGAGGACAACCTGACTTCC-3 248
Antisense: 5-TTGTGCTGTCCTTCCACTGC-3
Mouse Cfh NM_009888 Sense: 5-CAGGCTCGTGGTCAGAACAA-3 298
Antisense: 5-CCATCTGCACCACATTCACG-3
Mouse Bche NM_009738 Sense: 5-TGGATGGGAGTGATGCATGG-3 173
Antisense: 5-CACATTGTGCTATTGCCCTGG-3
Mouse Pgk1 NM_008828 Sense: 5-GGACAAGCTGGACGTGAAGG-3 256
Antisense: 5-ACAGAACATCCTTGCCCAGC-3
Plasmid
rtTA2S-M2 Sense: 5-GTCGGTATCGAAGGCCTGACG-3 304
Antisense: 5-ACAGGAACGCGAGCTGATTT-3
GLp65 Sense: 5-TGAACAGCGGATGAAAGAATCA-3
Antisense: 5-TTGACCTCATCTCCTCAAACTG-3 185
primer containing a T7 polymerase promoter-binding site
(Genset Oligos, La Jolla, CA). cDNA was then used as a tem-
plate to synthesize cRNA by in vitro transcription with T7
MEGAscript (Ambion, Austin, TX), in the presence of biotin-
ylated nucleotides (Enzo Diagnostics, Farmingdale, NY). La-
beled cRNAs were fragmented and hybridized to GeneChip
mouse genome 430A 2.0, using a Fluidics Station 450
(Affymetrix). Hybridized arrays were stained with strepta-
vidin–phycoerythrin, rewashed, treated with biotinylated anti-
streptavidin–phycoerythrin antibodies, and restained with
streptavidin–phycoerythrin, according to the manufacturer’s
protocols. The stained arrays were finally scanned in a Gene-
Array scanner (Hewlett Packard, Palo Alto, CA).
Microarray data analysis: normalization, signal calculation,
significant differential expression, and sample/gene
profiles clustering
Microarray data analysis was performed according to the
following strategy and methods. The RMA (robust multichip
average) algorithm was used for background correction, in-
tra- and intermicroarray normalization, and expression sig-
nal calculation (Bolstad et al., 2003; Irizarry et al., 2003a,b).
Once the absolute expression signal for each gene (i.e., the
signal value for each probe-set) was calculated for the whole
microarray set, the SAM (significance analysis of microar-
rays) algorithm (Tusher et al., 2001) was applied to calculate
significant differential expression and to find the gene probe-
sets that changed in each set of samples. The method uses
permutations to provide robust statistical inference of the
most significant probe sets and provides p values adjusted
to multiple testing, using the FDR (false discovery rate) (Ben-
jamini and Hochberg, 1995). Different FDR cutoffs were ap-
plied to different comparisons during the study, keeping al-
ways a significance threshold of an FDR less than 0.3, which
most of the time was less than 0.05 or less than 0.10.
After identification of the differentially expressed gene 
probe-sets, the corresponding matrix of expression values for
all performed microarray hybridizations was analyzed with
the hclust (hierarchical cluster function) algorithm (Murtagh,
1985). This algorithm performs hierarchical cluster analysis
with complete linkage to find similarity between gene probe-
sets on the basis of their expression values along all the an-
alyzed microarrays. The algorithm classifies gene probe-sets
in correlated groups presenting similar expression profiles
or expression signatures.
We applied all these methods using R and Bioconductor
as main computational and bioinformatic tools (www.
bioconductor.org; accessed October 2008). R is a program-
ming language and software environment for statistical com-
puting (www.r-project.org; accessed October 2008).
Functional analysis
Functional analysis of the significant genes obtained for
each induced state was done with a functional annotation
tool called GeneCodis (Gene Annotations Co-occurrence 
Discovery; see http://genecodis.dacya.ucm.es/) (Carmona-
Saez et al., 2007). This tool allows the user to find combina-
tions of co-occurrent annotations that are significantly asso-
ciated with a list of genes under study with respect to a
reference list. The significance of the annotations is calcu-
lated with a hypergeometric statistical test with FDR p value
correction and, using as reference, the mouse genome. The
annotations were done at the same time with reference to
the full Gene Ontology database (GO; http://www.geneon-
tology.org/; accessed October 2008) and to the KEGG path-
way database (KEGG; http://www.genome.ad.jp/kegg/
pathway.html; accessed October 2008). After the analyses
done with GeneCodis the redundancy on the list of genes
that are assigned to each functional class was depurated by
manual curation.
GFP expression
Mice were injected with 75 g of PGFPwpre by an HD pro-
cedure; 3 days later they were killed and livers were either
perfused with collagenase solution (Sigma-Aldrich) to iso-
late hepatocytes as described previously (Berasain et al.,
2005) or used to obtain sections that were frozen in O.C.T.
compound (Tissue-Tek; Sakura Finetek, Torrance, CA). GFP
expression in liver sections was visualized with an Eclipse
E800 (Nikon, Tokyo, Japan) fluorescence microscope. The
percentage of transfected cells was established by fluores-
cence-activated cell-sorting (FACS) analysis on isolated he-
patocytes resuspended in phosphate-buffered saline (PBS),
using a FACSCalibur analyzer (BD Biosciences, San Jose, CA)
with CellQuest Pro software analysis.
Measurement of plasma alanine aminotransferase and
aspartate aminotransferase levels
Plasma alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) levels were measured with a Hitachi
911 automatic analyzer (Hitachi, Tokyo, Japan). Values are
expressed as international units per liter (IU/liter).
Results
Determination of liver transfection efficiency and 
trans-activator expression
The aim of our study was to evaluate the effects of consti-
tutive expression of rtTA2S-M2 (rtTA2) or GLp65 in mouse
liver by transfection of hepatocytes with plasmids expressing
each of these TAs from a liver-specific promoter. To assess the
efficiency of liver transfection by hydrodynamic (HD) injec-
tion we first injected mice with 75 g of a plasmid carrying
GFP as a reporter gene (PGFPwpre). We used this amount of
plasmid because previous experiments performed with a plas-
mid encoding LacZ (pCMV) had shown that maximal trans-
fection efficiency was achieved with 50–100 g of DNA (data
not shown). Liver sections were examined by fluorescence mi-
croscopy at 72 hr posttransfection, revealing that a significant
amount of liver cells expressed the transgene (Fig. 1B). The
percentage of in vivo-transfected hepatocytes was determined
by isolating these cells after perfusion and subsequent analy-
sis by flow cytometry, showing that 17% of hepatocytes were
positive for GFP expression (Fig. 1C).
Plasmids EA-rtTA2 and EA-GLp65, carrying the rtTA2S-
M2 (rtTA2) or GLp65 gene downstream from the liver-spe-
cific EalbPa1AT promoter, respectively, were constructed as
described in Materials and Methods (Kramer et al., 2003) (Fig.
1A). To determine the level of expression for each TA, mice
(n  10) were injected by the HD procedure with 75 g of
EA-rtTA2 or EA-GLp65 plasmid, respectively. One month
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later, rtTA2 or GLp65 liver expression was determined by
quantitative RT-PCR (qRT-PCR) and compared with the ex-
pression level of Mat1a, which is a liver-specific gene. We
found that expression of both TAs was similar and about 6-
fold lower than that of Mat1a, which is expressed at a
medium to low level in hepatocytes (Fig. 1D). These data in-
dicated that in our experimental setting both rtTA2 and
GLp65 are expressed in a relatively high number of hepato-
cytes within physiological range levels.
Global transcriptomic effect due to rtTA2 or 
GLp65 expression in liver
To evaluate the constitutive effects of rtTA2 or GLp65 ex-
pression in the liver, groups of mice were injected by the HD
procedure with 75 g of plasmid EA-rtTA2 or EA-GLp65. In
each of these groups, half of the animals were treated with
the inducer drug (Dox or RU-486, respectively). Similar
groups of control noninjected animals were left untreated or
received only the inducer drug (Dox or RU-486, respec-
tively). One month after HD injection mice were killed and
mRNA was isolated from livers and analyzed by microar-
rays to evaluate gene expression changes caused by rtTA2
and GLp65 TAs.
A total set of 21 mRNA samples from different mouse liv-
ers was used to hybridize the mouse genome 430A 2.0 mi-
croarrays (Affymetrix). The samples were as follows: (1)
three controls, biological replicates of untreated mice; (2)
three treated with rtTA2; (3) three treated with GLp65; (4)
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FIG. 1. Schematic representation of vectors expressing TAs and analysis of in vivo transfection and expression. (A) The
EA-rtTA2 plasmid encodes rtTA2s-M2 TA, which is a fusion of the DNA-binding domain (DBD) of mutated bacterial tetra-
cycline repressor (rtetR) with three repeats of the herpes simplex virus protein 16 (VP16) activation domain (AD). The EA-
GLp65 plasmid encodes GLp65 TA, which is a fusion of the yeast GAL4 DBD (GAL4), a mutated human progesterone re-
ceptor ligand-binding domain (hPR LBD 19), and the human NF-B p65 subunit AD. Ealb, mouse albumin enhancer;
Pa1AT, human 1-antitrypsin promoter; SV40 late poly A, polyadenylation signal from simian virus 40 (SV40). (B and C)
Evaluation of in vivo transfection efficiency. BALB/c female mice were injected by a hydrodynamics (HD)-based procedure
with PGFPwpre plasmid and 3 days later GFP expression was analyzed by fluorescence in liver sections (B) or by flow cy-
tometry of hepatocytes isolated by liver perfusion (C). (D) Evaluation of TA expression in vivo. BALB/c female mice were
injected by the HD procedure with EA-rtTA2 or EA-GLp65 plasmids and 30 days later liver TA expression was quantified
by qRT-PCR. The graph shows the relative TA (rtTA2 or GLp65) transcript levels as compared with the endogenous liver-
specific gene Mat1a. The expression level of each TA was normalized for 17% of hepatocytes (estimated amount of trans-
fected hepatocytes), whereas Mat1a was normalized for 60% of liver cells (estimated amount of hepatocytes in liver). The
histogram corresponds to a representative experiment.
three treated with rtTA2 plus Dox; (5) three treated with
GLp65 plus RU-486; (6) three treated only with the drug Dox;
(7) three treated only with the drug RU-486.
To determine the effects of the TAs in the absence of the
inducer drug (i.e., TA in the nonactive form) we compared
the patterns of gene expression profile obtained from ani-
mals injected with plasmids encoding rtTA2 or GLp65 with
those of untreated control mice. After normalization and ex-
pression signal calculation, the SAM algorithm was used to
identify transcripts that showed a differential response be-
tween the compared groups (see Materials and Methods).
Quantitative differences at the level of gene expression be-
tween treated and control animals are shown in a plot (Fig.
2). Animals expressing rtTA2 showed a moderate effect, as
only 69 gene probe-sets were altered with an FDR of 0.05,
most of which were upregulated (Figs. 2A and 3). On the
other hand, GLp65 had more pronounced effects on gene ex-
pression because 1059 gene probe-sets were altered with an
FDR of 0.05 (Figs. 2D and 3). In this case the number of up-
regulated and downregulated probe-sets was similar and the
higher slope deviation from the diagonal (compare Fig. 2D
and A) indicates a more significant effect on the gene ex-
pression profiles. The number of altered gene probe-sets
found in these comparisons using a more open FDR of 0.10
showed the same tendency: 1138 probe-sets for rtTA2 and
5716 probe-sets for GLp65.
To test the effect of each TA in the presence of its corre-
sponding inducer drug (i.e., TA in the active form) we com-
pared gene expression profiles of mice injected with the TA-
expressing plasmid and treated with the inducer drug with
those of mice injected with the TA plasmid without the drug.
We found a small number of gene probe-sets altered either
by rtTA2 plus Dox (35 probe-sets at an FDR of 0.05) (Fig. 3)
or by GLp65 plus RU-486 (3 probe-sets at an FDR of 0.05)
(Fig. 3), suggesting that most of the effects caused by the TA
were already present in the absence of the inducer drug.
Regarding the effect of the drugs by themselves, we also
compared gene expression profiles between control mice
receiving Dox or RU-486, respectively, and untreated mice.
The administration of Dox altered only 10 gene probe-sets
at an FDR of 0.05 (14 at an FDR of 0.1) (Fig. 2C), mainly
upregulated. RU-486 administration had more pronounced
effects, causing differential expression of 95 gene probe-
sets at an FDR of 0.05 (which increased to 314 at an FDR
of 0.1), of which 37% were inhibited (Fig. 2F). A summary
of the number of altered gene probe-sets observed at an
FDR of 0.05 in each of the six contrasts mentioned is shown
in Fig. 3.
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As a means of establishing a more restrictive selection cri-
terion to determine the number of altered genes in each treat-
ment group we considered only those genes with an R-fold
absolute value of 	3 up- or downregulated (i.e., R-fold log2:
	3 for upregulated or 
0.33 for downregulated). In the case
of rtTA2, 25 gene probe-sets met this criterion (correspond-
ing to 20 different genes), being all upregulated. From these,
three genes corresponded to unknown genes that have not
been annotated yet, leaving 17 unique known genes (see
Table S1 at http://www.liebertonline.com/hum). GLp65
analysis provided 58 gene probe-sets altered (corresponding
to 53 different genes), all of them upregulated. Only 45 of
these were known, characterized genes (see Table S1). None
of these genes showed an R-fold value  10. The compari-
son of these two lists (see Table S1) shows that the top 17
genes altered by rtTA2 are also altered by GLp65, indicating
that both TAs have a similar gene alteration profile, at least
in the most significant region. The data also showed that
GLp65 provokes larger effects.
Microarray data validation
As the next step of the study, we focused on gene ex-
pression changes observed in animals treated only with the
inducer drugs, because these drugs have been widely used
and their side effects have been described extensively in the
literature. Moreover, the effects of drug intake should be ap-
preciated in all liver cells, which facilitates the validation of
changes observed.
Three lines of evidence supported the authenticity of the
changes observed in mice treated with the inducer drugs.
First, the internal coherence of the microarray was confirmed
when comparing data obtained with several probe-sets cor-
responding to the same differentially expressed gene. As
shown in Fig. 4A and B, multiple probe-sets corresponding
to representative genes displayed the same alteration direc-
tion with a similar fold change, indicating a high degree of
consistency for our analysis. Second, when four representa-
tive genes altered in each group (Dox or RU-486, respectively)
were analyzed by qRT-PCR the results confirmed not only a
strongly induced gene (Orm2), but also some other genes in-
duced moderately in the microarrays but clearly observed by
PCR (such as Col1a2 and Saa3; see Fig. 4C and D). The fold
changes determined by PCR for these genes were also con-
sistent with the fold changes determined by the microarrays.
Finally, the information previously recorded in the literature
about the effects associated with the administration of Dox
and RU-486 correlates well with changes observed in this
study. These changes include the upregulation of several
genes of the collagen family (Col1a1, Col1a2, Col3a1, Col5a2,
and Col6a2) in animals treated with Dox (see Table S2 at
http://www.liebertonline.com/hum), which correlates with
the profibrotic activity of this antibiotic (Lee et al., 2003;
Sapadin and Fleischmajer, 2006). In the case of RU-486 we ob-
served alteration of genes implicated in immunological func-
tions in animals treated with this drug (Bcan, Cfh, C1r, F13b,
and several interleukin receptors: Il1rn, Il10rb, and Il13ra1)
(see Table S3 at http://www.liebertonline.com/hum). These
findings are in keeping with the property of RU-486 to de-
press the innate immune system (Miech, 2005). It is also
known that RU-486 acts on steroid receptors, and we ob-
served several glucocorticoid and steroid hormone receptors
altered in RU-486-treated animals (Nr1d2 and Nr3c1) (Sitruk-
Ware, 2006).
Functional categorization of microarray data
To generate a functional profile for the genes altered by
the expression of each TA in mice we have used
GeneCodis, which is a Web-based tool for the ontological
analysis of large lists of genes (see Materials and Methods)
(Carmona-Saez et al., 2007). The functional profile con-
structed by GeneCodis for the 68 significant gene probe-
sets (60 genes) altered by rtTA2 (for an FDR of about 0.05)
(Table 2) revealed that the most significant functional al-
terations corresponded to some genes involved in apopto-
sis (Birc4, Casp3, Cflar, and Hipk2) and negative regula-
tion of cell cycle (Casp3, Hipk2, and Rb1cc1). Other
functions in which altered genes were found with lower
significance included translation initiation (Eif3s8, Eif3s10,
and Eif4g1). In the case of genes altered by GLp65, the 1058
significantly altered probe-sets (for an FDR of about 0.05)
corresponded mainly to genes involved in apoptosis (Birc4,
Casp3, Cflar, and Hipk2) and transport (Abca1, Abcb7,
Abcc2, and Abcd2) (see Table 2). Relevant pathways in
which GLp65 altered genes are implicated included mito-
gen-activated protein kinase (MAPK) signaling pathway
and ATP-binding cassette (ABC) transporters.
A functional analysis of genes altered by each TA in their
induced stage was also performed (taking genes with an FDR
cutoff of 0.1). According to GeneCodis, genes differentially
altered between the rtTA2 plus Dox group and the rtTA2
group corresponded, with a high degree of statistical proba-
bility, to collagen molecules implicated in cell adhesion,
acute-phase response proteins (Orm1, Orm2, Saa1, Saa2, and
Saa3), and lipid transporter activity associated with these pro-
teins (see Table S4 at http://www.liebertonline.com/hum).
Genes differentially expressed between the GLp65 plus RU-
486 group and the GLp65 group appeared to be implicated
in pathways related to regulation of actin cytoskeleton and
adherens junction (Actn4, Iqgap1, Mapk1, and Wasl). In ad-
dition, transcriptional activator activities were also signifi-
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cantly altered (Fus, Ppargc1a, and Sfpi1) in this group (see
Table S5 at http://www.liebertonline.com/hum).
To understand whether the effect of the TAs in the pres-
ence of the inducer drug was due to changes in the TA or to
the drug itself, data obtained from animals after drug ad-
ministration were also analyzed with the same functional an-
notation tool. GeneCodis analysis of the 95 probe-sets altered
(86 genes) after Dox administration (using an FDR cutoff of
0.3) revealed a significant presence of two families of genes
involved in the acute-phase response (Orm1, Orm2, Orm3,
Saa1, Saa2, and Saa3). The consistent appearance of five col-
lagen genes (Col1a1, Col1a2, Col3a1, Col5a2, and Col6a2)
and four genes related to membrane transporter activity
(Scl6a8, Scl6a12, Scl13a3, and Scl22a7) is also significant (see
Table S2). This correlates well with the main effect described
for active rtTA2, strongly suggesting that the additional ef-
fects observed when rtTA2 is activated by Dox are due
mainly to the drug itself, and not to a change in rtTA2.
GeneCodis analysis of data obtained from the RU-486-
treated animals showed a functional effect less focused on
specific gene families; rather, the effect was broader, affect-
ing biological processes more general and with a significant
effect on signal transduction and cell communication (see
Table S3), including some protein kinases and phosphatases
(Csnk2a1, Mapk, Ppp1cb, and Prkar2a). Alteration of these
genes shows that this drug may produce harsher physio-
logical effects. These processes were also significantly altered
in the GLp65 plus RU-486 group, suggesting that most of the
additional effects observed when GLp65 is activated by RU-
486 are also due to the drug itself.
Microarray data clustering
To achieve a more open and integrative analysis of the
transcriptomic profiles due to the specific effect of each TA,
the expression data corresponding to genes that change at
level of significance FDR  0.10 in animals treated with
rtTA2 plus Dox and with GLp65 plus RU-486 (Fig. 2B and
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FIG. 5. Hierarchical clustering of experimental groups receiving the TA proteins. Probe-sets found altered in the presence of
each TA plus inducer drug combination were used (p 
 0.001) after eliminating those present in the drug contrasts. The heat
map presents a grid of colored points, with each color representing a gene expression value in the sample: red corresponding
to high expression, green corresponding to low expression, and black corresponding to an intermediate level of expression.
Each column represents a sample and rows represent altered genes. The left margin dendrogram indicates three distinct clus-
ters of genes. Graphics on the right margin show the results of GeneCodis analysis of two clusters of genes that are upregu-
lated. The percentage of genes has been calculated with respect to the number of genes in each cluster. Ct, untreated; TA, rtTA2
treated; GL, GLp65 treated; Tad, mice receiving rtTA2 plus Dox; GLR, mice receiving GLp65 plus RU-486.
E) were taken and combined after subtracting genes altered
by the effect of the inducer drug alone. From these pools we
further selected the most significant genes, using a cutoff of
p  0.001 (i.e., gene-specific, differential expression adjusted
p  0.001). In this way, we identified a list of 223 altered gene
probe-sets that were used to explore the expression profiles
and patterns of samples and genes.
The analysis was done by means of semisupervised hier-
archical clustering, producing a heat map with the gene ex-
pression values of these 223 altered genes (see Fig. 5). With
respect to the samples, this analysis provided a clear clus-
tering of the biological replicates and the segregation of the
five sample types including a clear separation of the TAs
with and without the drug inducer (see top dendrogram in
Fig. 5). These results indicate reproducibility of the gene ex-
pression data obtained by multiple microarray experiments.
With respect to the genes, the heat map gives the overall
view that 223 genes group in three distinct clusters: the first
cluster is composed of 90 genes that are overexpressed in an-
imals treated with rtTA2 plus Dox (TAd1, -2, and -3); the sec-
ond cluster includes 83 genes overexpressed in animals
treated with GLp65 plus RU-486 (GLR1, -2, and -3); and the
third cluster contains 50 repressed genes also in this group.
Finally, considering that the genes altered only in response
to the drugs have been filtered out from this heat map, the
overall biological–functional trend of the overexpressed
genes showed similar results to those recorded for TA plus
inducer analysis (see Tables S5 and S6), with a larger effect
observed for GLp65 because it includes alterations in the pro-
cess of transcription, not present in the case of rtTA2. Of all
genes overexpressed in the presence of rtTA2 plus Dox (see
the heat map in Fig. 5) there was only one (Rasa1) also over-
expressed in the presence of rtTA2 without drug, which
means that the expression of all remaining 89 genes was due
only to the effect of rtTA2 in its active stage. However, this
is considering FDR  0.10 as threshold; when taking as a
level of significance FDR  0.05 (as indicated in Fig. 3) only
two of these genes (Dnajc14 and Atf4) would be included in
the heat map. In the same way, none of the genes overex-
pressed by the effect of GLp65 plus RU-486 included in the
heat map could be considered when using FDR  0.05, and
only three downregulated genes (Fus, Spr, and Vapb) would
be significant for this FDR value. Therefore, despite the in-
terest of the functional assignment done for the genes of the
heat map (Fig. 5), the overall effect of the TAs can be con-
sidered mild because it is not significant.
Evaluation of toxicity after constitutive expression of TAs
in liver
Alanine aminotransferase (AST [SGOT]) and aspartate
aminotransferase (ALT [SGPT]), which are sensitive indica-
tors of liver damage, were measured in samples of mouse
sera collected on day 0 (before plasmid injection) and day 30
(just before sacrifice). As shown in Fig. 6 no relevant changes
in ALT or AST levels were observed in any of the various
groups 1 month after treatment, with the exception of one
animal, from the rtTA2 plus Dox group, which showed a
moderate increase in ALT level.
Liver sections from animals belonging to the various
groups were stained with hematoxylin–eosin and analyzed
in order to determine whether any structural damage had
taken place. No relevant liver damage was observed by light
microscopy (data not shown).
Discussion
Gene-regulable systems have been used to activate or sup-
press the expression of transgenes encoded by long-term ex-
pression vectors. This is essential to adapt transgene ex-
pression to therapeutic needs and to avert the toxicity
derived from inappropriate levels of the encoded therapeu-
tic molecule. These regulable systems are based on the use
of a TA protein (expressed from a constitutive promoter),
which only in the presence of a specific drug (inducer) is able
to bind to the minimal inducible promoter that controls the
expression of the therapeutic transgene. Although TAs are
usually expressed at low levels, the fact that they are con-
tinuously present in the transduced cell could result in tox-
icity due to the activation or inactivation of nontarget genes.
The goal of the present study was to analyze the effects of
constitutive expression of the TAs from Tet-on and RU486-
on systems (rtTA2 and GLp65, respectively) on gene ex-
pression profiles in mouse liver. These two TAs were cho-
sen because they have been extensively used to regulate
expression of therapeutic genes in animal models and could
have a potential use in human patients (Wang et al., 2004;
Zabala et al., 2004). Therefore, analysis of their possible tox-
icity in vivo is essential before they can be used in gene ther-
apy clinical protocols.
To achieve TA expression in a high percentage of hepato-
cytes HD injection was used as an efficient method to achieve
efficient and durable transduction of liver cells (Liu et al.,
1999; Hodges and Scheule, 2003). Although this technique is
distant from clinical applications we decided to employ it
because the use of viral or nonviral vectors would introduce
additional components, such as viral proteins or synthetic
transducing agents, that could induce an undesired toxicity
or/and immunogenic reaction, making it more difficult to
determine the specific effects induced by the trans-activators
themselves.
We have previously shown that HD injection allowed sus-
tained protein expression over at least 50 days in mice re-
ceiving a plasmid containing the human 1-antitrypsin
(hAAT) gene controlled by the same promoter used in this
study (Kramer et al., 2003). In addition, experiments per-
formed in our laboratory showed that the amount of plas-
mid DNA transfected into mouse liver by hydrodynamic in-
jection remains constant between 7 and 120 days (our
unpublished data). Because transduction efficiency achieved
in the present study was about 20%, changes observed in
gene expression profiles are most likely attenuated with re-
spect to the changes taking place in the transfected cells, be-
cause whole liver was employed for transcriptome analysis.
However, this level of transduction was comparable to that
observed in gene therapy protocols based on delivery of ad-
enoviral vectors to the liver, indicating that the observed
changes will probably resemble those expected in a clinical
setting with a similar degree of transfection. Although 
other liver cells apart from hepatocytes could also have been
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FIG. 6. Analysis of toxicity. Alanine aminotransferase (ALT) and aspartate transferase (AST) levels were analyzed in sera
of mice from all experimental groups before treatment (t0) and 30 days later before sacrifice (t1). Control, mice that un-
derwent no treatment (n  7); Dox and RU, mice that received only the drug (n  7); rtTA2 and GLp65, mice that received
only the TA (n  5); rtTA2Dox and GLp65RU, mice that received the TA and its corresponding drug (n  5). The value
for each individual mouse is plotted.
transfected in our study, we believe that the observed
changes correspond mainly to hepatocytes because both
plasmids that were used contain a liver-specific promoter
(EalbPa1AT), restricting expression to these cells. Transcrip-
tomic changes were analyzed 1 month after HD injection be-
cause we considered it a length of time long enough to dis-
card possible side effects due to the transduction technique.
The effects produced by the drugs were more general, af-
fecting theoretically 100% of liver cells, which facilitates the
validation of the observed changes. Tetracyclines have been
reported to show some biological properties besides their an-
tibiotic effects, such as profibrogenic activity (Sapadin and
Fleischmajer, 2006). As an example, Dox has been extensively
used to inhibit collagenase in the treatment of periodontitis,
even though its mechanisms of action are not completely un-
derstood (Sapadin and Fleischmajer, 2006). On the other
hand, in vitro studies have shown that Dox administration
induces more collagen expression than transforming growth
factor-2 on rabbit mesothelial cells (Lee et al., 2003). Our mi-
croarray data showed that in the presence of Dox procolla-
gen-1 and other genes of the collagen family (Col1a2, Col1a1,
Col6a2, etc.) were upregulated, which correlates well with
the described effects of Dox on collagen synthesis. Mifepri-
stone (RU-486) is a synthetic steroid with potent antiprog-
esterone and antiglucocorticoid activities, being able to up-
regulate glucocorticoid receptors in the endometrium when
used as a contraceptive (Narvekar et al., 2006). In addition to
its other side effects, RU-486 has also been described as de-
pressing the innate immune system (Miech, 2005). In agree-
ment with these data, our microarray showed that in mice
receiving RU-486 there was both an upregulation of several
steroid receptors, such as Nr3c1 and Nr1d2, and an alter-
ation in a significant number of genes implicated in im-
munological processes. Changes in representative genes al-
tered in the Dox and RU-486 groups, such as Col1a2 and
Nr3c1, were also confirmed by RT-PCR analysis. Overall
cluster analysis showed a coherent behavior of the data, with
clear distinction and segregation of the samples of each
group. Finally, the fact that animals belonging to each ex-
perimental group were easily clustered together when ana-
lyzed by heat mapping supports the validity of the data.
In general, the data obtained from the microarray analy-
sis of animals expressing either rtTA2 or GLp65 in liver
showed a moderate effect on gene expression profiles. The
observed transcriptomic effect of rtTA2 versus control ani-
mals was weak, considering that is a genome-wide analysis
and alterations were observed for a reduced number of genes
(69 probe-sets with a significance FDR of 0.05). On the other
hand, GLp65 had a more pronounced effect on gene ex-
pression because 1059 probe-sets were altered with an FDR
of 0.05. In this analysis only 20 genes from the rtTA2 group
and 53 genes from the RU-486 group showed an alteration
with an R-fold  3, indicating that constitutive expression
of these TAs in the liver induce only moderate changes in
the transcriptome profile.
Our functional analysis showed that apoptosis and negative
regulation of cell cycle were the functions more affected in both
the rtTA2 and GLp65 groups, with a similar pattern of altered
genes (see Table 2). However, despite these transcriptional
changes the immunohistochemical analysis of liver samples
from mice expressing rtTA2 or GLp65 showed no increase in
apoptosis (data not shown) In this particular case, although func-
tional analysis revealed a group of four altered genes involved
in apoptosis (BIRC4, CASP3, CFLAR, and, HIPK2) (see Table 2),
only one of them (BIRC4) showed an R-fold value greater than
3 (see Table S1), indicating that these changes might not be
strong enough to cause manifest phenotypic alterations.
Other functions that were altered, with lower significance,
were translation initiation activities in rtTA2-expressing an-
imals and ABC transport and MAPK signaling in the GLp65
group. Mapk1 and Mapk14 overexpression was confirmed
by qRT-PCR in this group (data not shown), indicating that
this pathway may be affected by GLp65.
It was also important to analyze the global transcriptomic
effect induced by the TAs when they were in their active
form. To simplify this analysis we compared animals ex-
pressing rtTA2 or GLp65 and receiving Dox or RU-486, re-
spectively, with those animals that expressed only the cor-
responding TA. This comparison revealed that the active
drugs induced only discrete additional changes in gene ex-
pression with respect to their nonactive forms (35 altered
probe-sets for rtTA2 plus Dox and only 3 inhibited probe-
sets for GLp65 plus RU-486, with an FDR of 0.05). Most
changes observed in these contrasts were in fact due to the
effects produced by the inducer drugs by themselves. As
noted previously, in the case of rtTA2 plus Dox the most rel-
evant changes were those observed in the procollagen fam-
ily (Col) of structural proteins and in acute-phase proteins
of the serum amyloid (Saa) and orosomucoid (Orm) fami-
lies, which were also highly significant in mice receiving only
Dox. Both the moderate transcriptomic effects and the ab-
sence of liver toxicity induced by rtTA2 plus Dox are in
agreement with studies demonstrating the possibility of es-
tablishing stable hepatocyte-derived cell lines expressing
rtTA2 (Goldring et al., 2006). These results are in contrast
with the adverse effects described previously in cells ex-
pressing tTA, which is the repressor version of rtTA (Gossen
and Bujard, 1992; Gallia and Khalili, 1998). However, in this
case these toxic effects were most likely associated with the
VP16 AD present in tTA, which has been reduced in the
rtTA2 version. Moreover, in such studies tTA was expressed
from a promoter that could be activated by tTA itself, which
probably resulted in high levels of the activated TA, pro-
ducing morphological changes and alterations in the cell cy-
cle. In contrast, when tTA was expressed from a CMV pro-
moter, which is stronger than the EalbPa1AT promoter used
in the present study, no deleterious effects on cell cycle were
observed in transfected cells (Qin and Barsoum, 1997). An
additional piece of data supporting the lack of toxicity of the
TAs used in this study is that both Tet-on and Gal-4-based
regulatory systems have been successfully used to generate
transgenic mice (for a review see Lewandoski, 2001).
In summary, our findings demonstrate that the expression
of rtTA2 or GLp65 in liver of treated mice produces a mod-
est transcriptomic effect, which is not significantly enhanced
when the inducer drug is present. These results, together
with the absence of toxicity observed in treated animals, in-
dicate that Tet-on and RU486-on could constitute gene-reg-
ulatory systems with a good degree of safety for liver ex-
pression. The genome-wide view given by the microarrays
provides specific indication of which biological functions are
most affected and this view will help to determine any fur-
ther use or evaluation of these gene regulatory systems.
However, further toxicity analysis should be performed in
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nonhuman primates before applying these systems in hu-
man clinical protocols.
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